PD-020 Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with...

Por Faivre, S., Blanc, J.-F., Merle, P., Fasolo, A., Iacobellis, A., Grando, V., Decaens, T., Trojan, J., Villa, E., Stammberger, U., Bruns, R., Raymond, E.
Publicado no Ann Oncol (2016)